Reviewer’s report

Title: Single Arm NCRI Feasibility Study of CHOP in Combination with Ofatumumab in Induction and Maintenance for Patients with Newly Diagnosed Richter's Syndrome

Version: 1 Date: 9 November 2014

Reviewer: Bertrand Coiffier

Reviewer's report:

This is a proposal for a phase II study in Richter syndrome. The rational to use ofatumumab is very low considering that in DLBCL ofatumumab has a response rate below 10%. Why not using rituximab? Or doing a randomized phase II?

The role of ofatumumab in the future is near zero. When this study will be finished, the drug might have disappeared.

During all the paper the study/regimen is called CHOP-OR or CHOP-O. What is the meaning of this "R"? Is rituximab added in some patients?

Level of interest: An article of insufficient interest to warrant publication in a scientific/medical journal

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

No